Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05937074 · ClinicalTrials.gov registry record
Metabolic Response to Food in Lung Cancer
A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by Pennington Biomedical Research Center.
- Active
- Registry status
- 5
- Enrollment target
- 1
- Study location
NCT05937074: Active study of Carcinoma, Non-Small Cell Lung, sponsored by Pennington Biomedical Research Center.
NCT05937074 is a study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Pennington Biomedical Research Center. The registered enrollment target is 5 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05937074, a study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Pennington Biomedical Research Center.
- ACTIVE NOT RECRUITING
- Registry status
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This goal of this study is to describe how unintentional weight loss influences fasting and post-prandial metabolic flexibility in participants with advanced non-small cell lung cancer.
Primary Outcome
The respiratory quotient will be measured by indirect calorimetry before and after consumption of a liquid mixed meal
Conditions Studied
Interventions
- OTHER Weight loss (%)
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2026-06-30 |
What the registry record for NCT05937074 still lists
NCT05937074 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Weight loss (%) is the first listed.
NCT05937074 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT05937074 about?
NCT05937074 is a clinical study titled "Metabolic Response to Food in Lung Cancer". This goal of this study is to describe how unintentional weight loss influences fasting and post-prandial metabolic flexibility in participants with advanced non-small cell lung cancer.
What is the current status of trial NCT05937074?
This trial is currently active not recruiting. The enrollment target is 5 participants. The study started on 2023-07-18. Estimated completion is 2026-06-30.
What conditions does trial NCT05937074 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT05937074?
The interventions under investigation include: Weight loss (%) (OTHER).
Who is sponsoring clinical trial NCT05937074?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05937074 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05937074's enrollment target sits among peer trials
5 131st of 130 the lowest of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI